In Vitro Modulation of TrkB Receptor Signaling upon Sequential Delivery of Curcumin-DHA Loaded Carriers Towards Promoting Neuronal Survival
- 357 Downloads
To in vitro investigate the capacity of carrier-free and lipid-nanoparticle (NP)-encapsulated phytochemical compounds to prevent neuronal damage through neurotrophin potentiating activities. Delivery of molecules promoting the neurotrophin receptor signaling in the central nervous system (CNS) present ongoing interest for combination therapy development.
Super-resolution Stimulated Emission Depletion (STED) microscopy imaging and flow cytometry analysis were employed to study the expression of the neurotrophin TrkB receptor in a neuronal cell model, which is highly responsive to binding of brain-derived neurotrophic factor (BDNF). Dual drug-loaded nanoparticle formulations, prepared by self-assembly of lyotropic lipids and PEGylated amphiphile derivatives, were delivered to differentiated human neuroblastoma SH-SY5Y cells subjected to degenerative conditions.
The expression of BDNF in the intra and extracellular domains was quantified by ELISA and flow cytometry after sequential treatment of the degenerating SH-SY5Y cells by neurotherapeutic formulations. Flow cytometry was also used to assess the phosphorylation of the transcription factor cAMP response element-binding protein (CREB) in the intracellular domain as a result of the treatment by nanoformulations.
Over time, dual drug formulations (curcumin and docosahexaenoic acid (DHA)) promoted the neuronal survival and repair processes through enhanced BDNF secretion and increased phosphorylation of CREB as compared to untreated degenerating cells.
KEY WORDSBDNF CREB transcription factor curcumin DHA multidrug formulations
Brain-derived neurotrophic factor
Central nervous system
cAMP response element-binding protein
Enzyme-linked immunosorbent assay
Mitogen activated protein kinase
Phosphate buffered saline
Phosphatidylinositol-3 (PI3) kinase
Stimulated emission depletion
- Trk receptor
Tropomyosin-related kinase receptor.
ACKNOWLEDGEMENTS AND DISCLOSURES
The platform MIPSIT of the Paris-Saclay Institute of Therapeutic Innovation is acknowledged for facilities in super resolution STED and laser confocal imaging. L.G. thanks the European Commission for granting a fellowship through the SERP-Chem Erasmus Mundus program, Dr. S. Lesieur for admission in the lab, E. Millart and Dr. V. Faivre for advices in utilization of the high-pressure homogeneizer, and Dr. Rosana Simon for valuable help in flow cytometry technique. A.A. acknowledges financial support from ANR SIMI10 Nanosciences and Dr. S. Denis and Dr. J. Vergnaud-Gauduchon for advices in cell culture protocols.
- 3.Mariga A, Zavadil J, Ginsberg SD, Chao MV. Withdrawal of BDNF from hippocampal cultures leads to changes in genes involved in synaptic function. Dev Neurobiol. 2014;2014:57–64.Google Scholar
- 11.Fumagalli F, Racagni G, Riva MA. The expanding role of BDNF: a therapeutic target for Alzheimer’s disease? Pharm J. 2006;6:8–15.Google Scholar
- 13.Robinson RC, Radziejewski C, Spraggon G, Greenwald J, Kostura MR, Burtnick LD, et al. The structures of the neurotrophin-4 homodimer and the brain-derived neurotrophic factor/neurotrophin-4 heterodimer reveal a common Trk-binding site. Protein Sci. 1999;8:2589–97.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Bender RA, Lauterborn JC, Gall CM, Cariaga W, Baram TZ. Enhanced CREB phosphorylation in immature dentate gyrus granule cells precedes neurotrophin expression and indicates a specific role of CREB in granule cell differentiation. Eur J Neurosci. 2001;13:679–86.CrossRefPubMedPubMedCentralGoogle Scholar
- 58.Géral C, Angelova A, Angelov B, Nicolas V, Lesieur S. Chapter 11: multicompartment lipid nanocarriers for targeting of cells expressing brain receptors. In: Garti N, Somasundaran P, Mezzenga R, editors. Self-assembled supramolecular architectures: lyotropic liquid crystals. New Jersey: Wiley; 2012. p. 319–55.CrossRefGoogle Scholar
- 67.Herran E, Requejo C, Ruiz-Ortega JA, Aristieta A, Igartua M, Bengoetxea H, et al. Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease. Int J Nanomed. 2014;9:2677–87.Google Scholar
- 82.Wei YM, Guo JM, Zheng XL, Wu J, Zhou Y, Yu Y, et al. Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes. Int J Nanomed. 2014;9:3623–30.Google Scholar
- 91.Encinas M, Iglesias M, Liu YH, Wang HY, Muhaisen A, Cena V, et al. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem. 2000;75:991–1003.CrossRefPubMedGoogle Scholar
- 95.Zhang SH, Zhou X, Rush RA. Extraction and quantification of the neurotrophins. In: Neurotrophin Protocols. Totowa, USA: Humana Press; 2001. p. 31–41.Google Scholar